ANTX - AN2 Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANTX is currently covered by 1 analysts with an average price target of $4.26. This is a potential upside of $3.16 (287.27%) from yesterday's end of day stock price of $1.1.

AN2 Therapeutics's activity chart (see below) currently has 26 price targets and 27 ratings on display. The stock rating distribution of ANTX is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 29.17% with an average time for these price targets to be met of 69 days.

Highest price target for ANTX is $2, Lowest price target is $2, average price target is $2.

Most recent stock forecast was given by ROY BUCHANAN from JMP on 05-May-2025. First documented stock forecast 19-Apr-2022.

Best performing analysts who are covering ANTX - AN2 Therapeutics:

Kevin Degeeter Joseph Schwartz Liisa Bayko Roy Buchanan

Currently out of the existing stock ratings of ANTX, 4 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$2

$0.94 (88.68%)

$5

7 months 1 days ago
(05-May-2025)

0/8 (0%)

$0.8 (66.67%)

Hold

$1

$-0.06 (-5.66%)

1 years 3 months 27 days ago
(09-Aug-2024)

1/3 (33.33%)

$-0.03 (-2.91%)

7

Hold

$2

$0.94 (88.68%)

$7

1 years 6 months 20 days ago
(16-May-2024)

1/3 (33.33%)

$-0.27 (-11.89%)

15

Buy

$27

$25.94 (2447.17%)

$24

2 years 2 months 23 days ago
(13-Sep-2023)

2/4 (50%)

$12.12 (81.45%)

254

Show more analysts

Please expand the browser size to see the chart

What is ANTX (AN2 Therapeutics) average time for price targets to be met?

On average it took 69 days on average for the stock forecasts to be realized with a an average price target met ratio 29.17

Which analyst has the current highest performing score on ANTX (AN2 Therapeutics) with a proven track record?

KEVIN DEGEETER

Which analyst has the current lower performing score on ANTX (AN2 Therapeutics) with a proven track record?

ROY BUCHANAN

Which analyst has the most public recommendations on ANTX (AN2 Therapeutics)?

Kevin Degeeter works at LADENBURG and has 4 price targets and 2 ratings on ANTX

Which analyst is the currently most bullish on ANTX (AN2 Therapeutics)?

Kevin Degeeter with highest potential upside - $25.94

Which analyst is the currently most reserved on ANTX (AN2 Therapeutics)?

Joseph Schwartz with lowest potential downside - -$0.06

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?